T3512 |
S49076 HCl
|
1265966-31-1
|
|
|
S49076 HCl (S-49076 Hydrochloride) is an effective inhibitor of MET, AXL/MER, and FGFR1/2/3. S49076 HCl potently blocked cellular phosphorylation of MET, AXL, an...
|
T79045 |
AXL-IN-15
|
1954722-22-5
|
98%
|
|
AXL-IN-15 (cpd391) is a potent inhibitor of Axl, exhibiting both a dissociation constant (K i) and a half-maximal inhibitory concentration (IC50) of less than 1 ...
|
T79969 |
Axl-IN-16
|
|
98%
|
|
Axl-IN-16, a dual Axl/HIF inhibitor, promotes Flammulina velutipes fruiting body formation and suppresses hypoxia-inducible factor activity along with receptor t...
|
T12650 |
R916562
|
1037798-41-6
|
98%
|
|
R916562 is an orally active and selective Axl/VEGF-R2 inhibitor with IC50s of 136 nM and 24 nM, respectively. R916562 has anti-angiogenesis and anti-metastasis.
|
T73310 |
AXL-IN-14
|
2947506-65-0
|
98%
|
|
AXL-IN-14 is a potent, orally active inhibitor of AXL with an IC50 of 0.8 nM that effectively suppresses Gas6/AXL-mediated cell migration and invasion, reduces t...
|
T12925 |
Sitravatinib malate
|
2244864-88-6
|
98%
|
|
Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 ...
|
T2586 |
Cabozantinib
|
849217-68-1
|
99.88%
|
|
Cabozantinib (BMS-907351) (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 ...
|
T1968 |
UNC2250
|
1493694-70-4
|
99.78%
|
|
UNC2250 is an effective and specific Mer inhibitor (IC50=1.7 nM).
|
TQ0041 |
Ningetinib Tosylate
|
1394820-77-9
|
99.77%
|
|
Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
|
TQ0021 |
Ningetinib
|
1394820-69-9
|
99.77%
|
|
Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
|
T13074 |
TAM-IN-2
|
2135642-56-5
|
99.74%
|
|
TAM-IN-2 is an inhibitor of TAM.
|
T7007 |
UNC2025
|
1429881-91-3
|
99.74%
|
|
UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl...
|
T6269 |
Bemcentinib
|
1037624-75-1
|
99.73%
|
|
Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.
|
T2629 |
UNC2881
|
1493764-08-1
|
99.72%
|
|
UNC2881 is a specific Mer tyrosine kinase inhibitor (IC50: 4.3 nM). It is about 83- and 58-fold higher selectivity than Axl and Tyro3, respectively.
|
T4409 |
Gilteritinib
|
1254053-43-4
|
99.72%
|
|
Gilteritinib (ASP2215) is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectivel...
|
T4419 |
UNC2025 2HCl (1429881-91-3(free base))
|
T4419
|
99.71%
|
|
UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
|
T4213 |
NCT-503
|
1916571-90-8
|
99.56%
|
|
NCT-503 is an inhibitor of 3-phosphoglycerate dehydrogenase (PHGDH), inhibiting serine synthesis from 3-phosphoglycerate in cells.
|
T9052 |
XL092
|
2367004-54-2
|
99.51%
|
|
XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.
|
T17205 |
UNC2541
|
1612782-86-1
|
99.46%
|
|
UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor. It also binds in the MerTK ATP pocket (IC50: 4.4 nM). UNC2541 inhibits phosphorylated Mer...
|
T16806 |
RU-302
|
1182129-77-6
|
99.45%
|
|
RU-302 is a pan inhibitor of TAM Receptor blocking the interface between the TAM Ig1 ectodomain and the Gas6 Lg domain. RU-302 effectively blocks the activation ...
|